(MISSISSAUGA, Ontario) – MedX Health Corp. is pleased to announce that it has completed the design phase of its telemedicine platform which will allow MedX’s scanning devices to be deployed in multiple points of service in North America and internationally. The scanned images will be sent securely to dermatologists for remote assessment, allowing for accelerated referral for patients to an in-person consultation with a dermatologist for the treatment of suspicious cases.
“We are very excited about reaching this important milestone with Blanc Labs as we believe that this telemedicine platform is a game-changer for MedX and its growth trajectory, and ultimately for people – no matter where they live – who will be able to get their moles and lesions accurately assessed by a dermatologist without having to endure lengthy wait times to determine if there is cancer present,” said Robert von der Porten, President and Chief Executive Officer of MedX. “It brings the advantages of telemedicine to the growing skin cancer problem, while offering the benefits of software as a service (SaaS). We are confident that the deployment of our system, which will be available early in 2018, will help reduce patient wait times, healthcare costs and mortality rates.”
“Blanc Labs is very proud to have been chosen by MedX to collaborate with them on this project,” said Dariush Zomorrodi, Blanc Lab’s Chief Innovation Officer. “Our partnership will allow us to continue to be innovators in building this platform. Skin cancer is a massive global issue and we see the telemedicine platform as a way to help dramatically reduce skin cancer’s human, financial and emotional toll.”
According to the Canadian Cancer Society, melanoma is the deadliest form of skin cancer but when caught early it is largely curable. Frequent skin screenings, early detection and a strong focus on prevention are all necessary to stop the rise in melanoma cases.
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.
Blanc Labs accelerates innovation for financial institutions and other industry leaders through a core focus on emerging technologies. Headquartered in Toronto, the firm builds cutting-edge technology in full partnership with clients in North & South America. We empower clients to enhance their digital offerings and bring creative solutions to market faster.